 Benjamin Frank
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 17 | 2025 | 1905 | 3.330 |
Why?
| | Heart Defects, Congenital | 14 | 2025 | 833 | 1.910 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2022 | 382 | 1.690 |
Why?
| | Hernias, Diaphragmatic, Congenital | 2 | 2023 | 201 | 1.320 |
Why?
| | Fontan Procedure | 5 | 2024 | 180 | 1.240 |
Why?
| | Endothelin-1 | 2 | 2022 | 182 | 1.210 |
Why?
| | Pulmonary Artery | 9 | 2025 | 1086 | 1.190 |
Why?
| | Echocardiography | 7 | 2025 | 642 | 1.080 |
Why?
| | Ventricular Dysfunction, Right | 4 | 2023 | 235 | 1.070 |
Why?
| | Kynurenine | 3 | 2024 | 114 | 1.050 |
Why?
| | Cardiopulmonary Bypass | 8 | 2025 | 209 | 1.040 |
Why?
| | Tryptophan | 3 | 2024 | 183 | 1.010 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 527 | 0.990 |
Why?
| | Cardiac Surgical Procedures | 6 | 2024 | 530 | 0.930 |
Why?
| | Infant | 23 | 2025 | 9395 | 0.930 |
Why?
| | Hemodynamics | 11 | 2025 | 1110 | 0.910 |
Why?
| | Acetamides | 1 | 2024 | 36 | 0.870 |
Why?
| | Matrix Metalloproteinase 8 | 1 | 2023 | 8 | 0.850 |
Why?
| | Citrulline | 1 | 2024 | 45 | 0.850 |
Why?
| | Pyrazines | 1 | 2024 | 90 | 0.840 |
Why?
| | Nitric Oxide | 3 | 2024 | 915 | 0.830 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 291 | 0.810 |
Why?
| | Heart Ventricles | 9 | 2024 | 785 | 0.810 |
Why?
| | Blood Proteins | 2 | 2020 | 252 | 0.780 |
Why?
| | Arginine | 1 | 2024 | 271 | 0.780 |
Why?
| | Aortic Coarctation | 2 | 2023 | 83 | 0.760 |
Why?
| | Heart Bypass, Right | 1 | 2022 | 17 | 0.760 |
Why?
| | Infant, Premature, Diseases | 2 | 2023 | 100 | 0.750 |
Why?
| | Ventricular Function, Left | 4 | 2023 | 533 | 0.680 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2020 | 69 | 0.670 |
Why?
| | Child | 28 | 2025 | 21819 | 0.660 |
Why?
| | Heart Diseases | 1 | 2023 | 346 | 0.660 |
Why?
| | Heart Function Tests | 1 | 2019 | 59 | 0.640 |
Why?
| | Infant, Newborn | 15 | 2025 | 6032 | 0.630 |
Why?
| | Prospective Studies | 11 | 2024 | 7572 | 0.610 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.600 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2019 | 26 | 0.600 |
Why?
| | Biomarkers | 8 | 2024 | 4144 | 0.580 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2019 | 130 | 0.570 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2023 | 382 | 0.570 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 328 | 0.560 |
Why?
| | Humans | 57 | 2025 | 136765 | 0.550 |
Why?
| | Pediatrics | 2 | 2024 | 1094 | 0.530 |
Why?
| | Ventricular Remodeling | 1 | 2019 | 262 | 0.520 |
Why?
| | Treatment Outcome | 11 | 2025 | 10745 | 0.450 |
Why?
| | Retrospective Studies | 14 | 2025 | 15504 | 0.440 |
Why?
| | Pain | 1 | 2019 | 754 | 0.410 |
Why?
| | Familial Primary Pulmonary Hypertension | 4 | 2022 | 198 | 0.410 |
Why?
| | Computed Tomography Angiography | 2 | 2025 | 125 | 0.410 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 26 | 0.380 |
Why?
| | Adolescent | 15 | 2025 | 21382 | 0.380 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2025 | 121 | 0.370 |
Why?
| | Male | 27 | 2025 | 67311 | 0.360 |
Why?
| | Ventricular Function, Right | 3 | 2023 | 282 | 0.360 |
Why?
| | Pulmonary Veins | 2 | 2023 | 99 | 0.350 |
Why?
| | Hypoxia | 3 | 2024 | 1112 | 0.350 |
Why?
| | Atrial Function, Right | 2 | 2021 | 12 | 0.340 |
Why?
| | Heart Failure | 1 | 2024 | 2231 | 0.340 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 487 | 0.340 |
Why?
| | Vasodilator Agents | 2 | 2025 | 331 | 0.340 |
Why?
| | Myocardial Contraction | 3 | 2020 | 339 | 0.330 |
Why?
| | Female | 26 | 2025 | 72795 | 0.320 |
Why?
| | Predictive Value of Tests | 6 | 2025 | 2022 | 0.310 |
Why?
| | Microfilament Proteins | 4 | 2003 | 131 | 0.310 |
Why?
| | Pulmonary Valve | 1 | 2010 | 97 | 0.310 |
Why?
| | Length of Stay | 4 | 2025 | 1205 | 0.310 |
Why?
| | Postoperative Complications | 5 | 2021 | 2639 | 0.300 |
Why?
| | Case-Control Studies | 4 | 2024 | 3539 | 0.280 |
Why?
| | Palliative Care | 3 | 2025 | 752 | 0.280 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 2 | 2025 | 25 | 0.280 |
Why?
| | Child, Preschool | 10 | 2025 | 10997 | 0.270 |
Why?
| | Tissue Engineering | 1 | 2010 | 418 | 0.260 |
Why?
| | Morbidity | 2 | 2024 | 323 | 0.250 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2023 | 193 | 0.250 |
Why?
| | Carrier Proteins | 4 | 2003 | 769 | 0.240 |
Why?
| | Vascular Stiffness | 2 | 2021 | 493 | 0.240 |
Why?
| | Hemorrhage | 2 | 2021 | 721 | 0.240 |
Why?
| | Proteomics | 2 | 2023 | 1109 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3555 | 0.230 |
Why?
| | SOXF Transcription Factors | 1 | 2024 | 16 | 0.230 |
Why?
| | Kynurenic Acid | 1 | 2024 | 20 | 0.230 |
Why?
| | Multidetector Computed Tomography | 1 | 2025 | 39 | 0.230 |
Why?
| | Norwood Procedures | 1 | 2025 | 29 | 0.230 |
Why?
| | Graft Occlusion, Vascular | 1 | 2025 | 40 | 0.230 |
Why?
| | Serotonin | 2 | 2024 | 323 | 0.230 |
Why?
| | Echocardiography, Doppler | 1 | 2025 | 108 | 0.220 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2023 | 26 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2022 | 809 | 0.210 |
Why?
| | History, 21st Century | 1 | 2024 | 212 | 0.210 |
Why?
| | Prognosis | 2 | 2023 | 4013 | 0.200 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2023 | 38 | 0.200 |
Why?
| | Stenosis, Pulmonary Vein | 1 | 2023 | 17 | 0.200 |
Why?
| | Models, Cardiovascular | 2 | 2024 | 195 | 0.200 |
Why?
| | Vascular Resistance | 1 | 2024 | 372 | 0.200 |
Why?
| | History, 20th Century | 1 | 2024 | 324 | 0.200 |
Why?
| | Infant, Extremely Premature | 1 | 2023 | 66 | 0.200 |
Why?
| | Stroke Volume | 2 | 2023 | 612 | 0.200 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2022 | 43 | 0.190 |
Why?
| | Atrioventricular Block | 1 | 2022 | 37 | 0.190 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 153 | 0.190 |
Why?
| | Phenylpropionates | 1 | 2022 | 19 | 0.190 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2023 | 173 | 0.180 |
Why?
| | Pyridazines | 1 | 2022 | 56 | 0.180 |
Why?
| | Amino Acids | 1 | 2025 | 497 | 0.180 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2021 | 19 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2003 | 337 | 0.180 |
Why?
| | Protein Conformation | 2 | 2003 | 933 | 0.180 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 267 | 0.180 |
Why?
| | Ventricular Function | 1 | 2021 | 61 | 0.180 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2003 | 610 | 0.180 |
Why?
| | Postoperative Period | 1 | 2022 | 342 | 0.170 |
Why?
| | Administration, Inhalation | 2 | 2021 | 683 | 0.170 |
Why?
| | Matrix Metalloproteinases | 1 | 2021 | 95 | 0.170 |
Why?
| | Pulmonary Atresia | 1 | 2020 | 21 | 0.170 |
Why?
| | Preoperative Period | 1 | 2020 | 129 | 0.170 |
Why?
| | Heart Atria | 1 | 2021 | 137 | 0.160 |
Why?
| | Metabolomics | 3 | 2021 | 678 | 0.160 |
Why?
| | Proteome | 1 | 2024 | 472 | 0.160 |
Why?
| | Societies, Medical | 1 | 2024 | 816 | 0.160 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 229 | 0.160 |
Why?
| | Electrophysiological Phenomena | 1 | 2019 | 58 | 0.160 |
Why?
| | Risk Factors | 4 | 2023 | 10325 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2023 | 528 | 0.160 |
Why?
| | Lung | 3 | 2023 | 4062 | 0.150 |
Why?
| | Gingiva | 1 | 2019 | 25 | 0.150 |
Why?
| | Mechanical Phenomena | 1 | 2019 | 84 | 0.150 |
Why?
| | Regional Blood Flow | 1 | 2021 | 473 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 19 | 0.150 |
Why?
| | Infant, Premature | 2 | 2023 | 566 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2019 | 60 | 0.150 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 405 | 0.150 |
Why?
| | Transcriptome | 1 | 2025 | 969 | 0.150 |
Why?
| | Chest Pain | 1 | 2019 | 90 | 0.150 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 253 | 0.150 |
Why?
| | Alkaline Phosphatase | 1 | 2019 | 148 | 0.150 |
Why?
| | Endotoxemia | 1 | 2019 | 86 | 0.140 |
Why?
| | Endotoxins | 1 | 2019 | 220 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 688 | 0.140 |
Why?
| | Ascorbic Acid | 1 | 2019 | 176 | 0.140 |
Why?
| | Leg | 1 | 2019 | 236 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2023 | 747 | 0.130 |
Why?
| | Cohort Studies | 2 | 2024 | 5701 | 0.130 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2021 | 752 | 0.130 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 597 | 0.130 |
Why?
| | Iron | 1 | 2019 | 312 | 0.130 |
Why?
| | Risk | 1 | 2019 | 908 | 0.130 |
Why?
| | Swine | 3 | 2025 | 773 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 1997 | 106 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 532 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1261 | 0.120 |
Why?
| | Actins | 3 | 2003 | 416 | 0.120 |
Why?
| | Intubation, Intratracheal | 1 | 1997 | 257 | 0.110 |
Why?
| | Down Syndrome | 1 | 2021 | 490 | 0.110 |
Why?
| | Lung Diseases | 1 | 2021 | 768 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 559 | 0.110 |
Why?
| | Stents | 2 | 2025 | 527 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6808 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 1036 | 0.100 |
Why?
| | Blood Pressure | 1 | 2019 | 1774 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2019 | 755 | 0.090 |
Why?
| | Amino Acid Sequence | 4 | 2003 | 2138 | 0.090 |
Why?
| | Molecular Sequence Data | 4 | 2003 | 2894 | 0.090 |
Why?
| | Diastole | 2 | 2022 | 149 | 0.090 |
Why?
| | Drainage | 1 | 2011 | 171 | 0.090 |
Why?
| | Purines | 2 | 2022 | 176 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 323 | 0.080 |
Why?
| | Bile Duct Neoplasms | 1 | 2011 | 123 | 0.080 |
Why?
| | Adult | 3 | 2023 | 37631 | 0.080 |
Why?
| | Anastomosis, Surgical | 2 | 2021 | 152 | 0.080 |
Why?
| | Cholestasis | 1 | 2011 | 232 | 0.070 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2002 | 340 | 0.070 |
Why?
| | Metabolome | 2 | 2021 | 350 | 0.070 |
Why?
| | Peptide Fragments | 2 | 2003 | 705 | 0.070 |
Why?
| | Keratan Sulfate | 1 | 2006 | 1 | 0.060 |
Why?
| | Histidine | 2 | 2003 | 64 | 0.060 |
Why?
| | Synovial Fluid | 1 | 2006 | 67 | 0.060 |
Why?
| | Protein Folding | 3 | 2002 | 280 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2006 | 135 | 0.060 |
Why?
| | Circular Dichroism | 2 | 2002 | 149 | 0.060 |
Why?
| | Organ Specificity | 1 | 2025 | 304 | 0.050 |
Why?
| | Language Development | 1 | 2024 | 61 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2006 | 222 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2024 | 71 | 0.050 |
Why?
| | Syndrome | 1 | 2024 | 357 | 0.050 |
Why?
| | Osteoarthritis | 1 | 2006 | 185 | 0.050 |
Why?
| | Erythrocyte Membrane | 1 | 2003 | 55 | 0.050 |
Why?
| | Models, Molecular | 3 | 2003 | 1570 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2020 | 3710 | 0.050 |
Why?
| | Serine | 1 | 2003 | 141 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2475 | 0.050 |
Why?
| | Binding Sites | 2 | 2003 | 1301 | 0.050 |
Why?
| | Protein Structure, Tertiary | 2 | 2002 | 860 | 0.050 |
Why?
| | Molecular Structure | 1 | 2003 | 489 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2024 | 429 | 0.050 |
Why?
| | Tadalafil | 1 | 2022 | 7 | 0.050 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2002 | 86 | 0.050 |
Why?
| | Phenylalanine | 1 | 2002 | 68 | 0.050 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2022 | 37 | 0.050 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2021 | 16 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 187 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2002 | 374 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2002 | 306 | 0.040 |
Why?
| | Niacinamide | 1 | 2021 | 79 | 0.040 |
Why?
| | Methionine | 1 | 2021 | 160 | 0.040 |
Why?
| | Arterial Pressure | 1 | 2021 | 126 | 0.040 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2020 | 36 | 0.040 |
Why?
| | Gestational Age | 1 | 2023 | 902 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 41 | 0.040 |
Why?
| | Survival Rate | 2 | 2011 | 1963 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 973 | 0.040 |
Why?
| | Systole | 1 | 2020 | 189 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2020 | 140 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 351 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 194 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 664 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1758 | 0.040 |
Why?
| | Time | 1 | 2019 | 82 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2022 | 1062 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 629 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 433 | 0.040 |
Why?
| | Animals | 5 | 2025 | 36847 | 0.040 |
Why?
| | Myocardium | 1 | 2023 | 1001 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1692 | 0.040 |
Why?
| | Aorta | 1 | 2020 | 417 | 0.030 |
Why?
| | Escherichia coli | 1 | 2002 | 806 | 0.030 |
Why?
| | Electrophysiologic Techniques, Cardiac | 1 | 2018 | 82 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1772 | 0.030 |
Why?
| | Nevada | 1 | 1997 | 9 | 0.030 |
Why?
| | Poisson Distribution | 1 | 1997 | 73 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3265 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2018 | 412 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2020 | 738 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1167 | 0.030 |
Why?
| | Confidence Intervals | 1 | 1997 | 328 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1940 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1571 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1997 | 233 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2018 | 576 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1467 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 901 | 0.030 |
Why?
| | Oxygen | 1 | 2018 | 930 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2667 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2021 | 5106 | 0.020 |
Why?
| | Retreatment | 1 | 2011 | 72 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3284 | 0.020 |
Why?
| | Catheterization | 1 | 2011 | 179 | 0.020 |
Why?
| | Chickens | 2 | 2002 | 191 | 0.020 |
Why?
| | Radiography, Interventional | 1 | 2011 | 113 | 0.020 |
Why?
| | Incidence | 1 | 1997 | 2792 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3432 | 0.020 |
Why?
| | United States | 1 | 2024 | 14690 | 0.020 |
Why?
| | Bone Morphogenetic Protein 7 | 1 | 2006 | 10 | 0.020 |
Why?
| | Protein Binding | 2 | 2002 | 2216 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 816 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13127 | 0.010 |
Why?
| | Autoantigens | 1 | 2006 | 428 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 2002 | 127 | 0.010 |
Why?
| | Knee Joint | 1 | 2006 | 409 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 345 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2002 | 385 | 0.010 |
Why?
| | Plasmids | 1 | 2002 | 360 | 0.010 |
Why?
| | Cytoskeleton | 1 | 2002 | 188 | 0.010 |
Why?
| | Titrimetry | 1 | 1999 | 12 | 0.010 |
Why?
| | Consensus Sequence | 1 | 1999 | 73 | 0.010 |
Why?
| | Static Electricity | 1 | 1999 | 118 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 108 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2002 | 390 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7585 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 1999 | 225 | 0.010 |
Why?
| | Temperature | 1 | 2002 | 675 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 374 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1350 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1664 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1999 | 560 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2052 | 0.010 |
Why?
| | Thermodynamics | 1 | 1999 | 401 | 0.010 |
Why?
| | Software | 1 | 2002 | 665 | 0.010 |
Why?
| | Aged | 1 | 2011 | 23794 | 0.010 |
Why?
| | Middle Aged | 1 | 2011 | 33228 | 0.000 |
Why?
|
|
Frank's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|